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ReviewTOR, a Central Controller
of Cell Growth
growth is compounded by the need to adhere to an
overall body plan during development. For example, the
different organs of the body need to grow to a specific
Tobias Schmelzle and Michael N. Hall*
Department of Biochemistry
Biozentrum, University of Basel
Klingelbergstrasse 70 size to maintain body proportions. To achieve an appro-
priate cell, organ, or organism size, cell growth must beCH-4056 Basel
Switzerland coordinately controlled with cell proliferation and, in the
case of metazoans, cell death. How is cell growth con-
trolled, and how is this control integrated with that of
cell proliferation and death?Summary
Cell growth (increase in cell mass) and cell proliferation In recent years, interest in cell growth has been rekin-
dled as it has become apparent that elaborate mecha-(increase in cell number) are distinct yet coupled pro-
cesses that go hand-in-hand to give rise to an organ, nisms actively control cell growth in response to favor-
able conditions. Cell growth is not passively controlledorganism, or tumor. Cyclin-dependent kinase(s) is the
central regulator of cell proliferation. Is there an equiva- simply by the availability of nutrients (building blocks),
as was widely thought 30 years ago when Hartwell de-lent regulator for cell growth? Recent findings reveal
that the target of rapamycin TOR controls an unusually cided to focus on his cell division mutants, but by signal-
ing pathways that impinge on general cell physiologyabundant and diverse set of readouts all of which are
important for cell growth, suggesting that this conserved to elicit balanced macromolecular synthesis. There is
growing evidence that the TOR kinase plays a centralkinase is such a central regulator.
role in controlling these pathways and thus the various
readouts that determine cell growth.Background
In the late 1960s, Lee Hartwell isolated approximately
400 temperature-sensitive yeast mutants which he then The TOR Protein
characterized for macromolecular synthesis (protein TOR (target of rapamycin) was originally identified ge-
and RNA synthesis), cell division, and cell morphology netically by mutations in yeast, TOR1–1 and TOR2–1,
(Hartwell, 1967). He subsequently chose to focus on the that confer resistance to the growth-inhibitory proper-
mutants that displayed defects in cell division, the now ties of the immunophilin–immunosuppressant complex
famous cdc mutants. Importantly, Hartwell made a dis- FKBP (FK506 binding protein)-rapamycin (Heitman et
tinction between cell proliferation and cell growth. Prolif- al., 1991). The TOR1 and TOR2 genes encode the two
eration is cell division which leads to an increase in cell large (molecular weight z280 kDa) and highly homolo-
number, whereas growth is macromolecular synthesis gous (70% identical) TOR1 and TOR2 proteins (Kunz
which leads to an increase in cell mass or size. A fortu- et al., 1993; Helliwell et al., 1994). The structurally and
nate consequence of Hartwell’s decision to focus on cell functionally conserved mammalian counterpart mTOR
division was that we now have a relatively sophisticated (also known as FRAP, RAFT, or RAPT) was subsequently
understanding of the mechanisms that control the cell discovered biochemically based on its FKBP-rapamycin
cycle. An inadvertent and unfortunate fallout from this binding properties (Brown et al., 1994; Chiu et al., 1994;
decision, however, was that the study of cell growth, Sabatini et al., 1994; Sabers et al., 1995). More recently,
and in particular the mechanisms that control it, have single TOR homologs have been found encoded in the
been largely neglected. To make matters worse and fly and worm genomes.
confusing, the distinction between growth and prolifera- The TORs contain a C-terminal region with strong
tion has also been lost; it is common to find in the homology to the catalytic domain of phosphatidylinosi-
literature the terms “growth” and “proliferation” incor- tol 3-kinase (PI3K) and phosphatidylinositol 4-kinase
rectly used interchangeably. Cell growth and cell prolif- (Kunz et al., 1993; Keith and Schreiber, 1995) (Figure 1).
eration are indeed separable and thus distinct pro- Studies in yeast, flies, and mammals have revealed a
cesses, as revealed by Hartwell’s mutants and others’ TOR-related family of proteins which includes MEC1,
studies (Hartwell, 1967; Mitchison, 1971; Thomas and TEL1, RAD3, MEI-41, DNA-PK, ATM, ATR, and TRRAP.
Hall, 1997; Neufeld and Edgar, 1998; Conlon and Raff, All these proteins contain a characteristic C-terminal
1999). phosphatidylinositol (PI) kinase homology domain and
Growth is not simply an accumulation of mass. It is a have thus been termed PI kinase (PIK)-related kinases.
carefully orchestrated accumulation of mass, occurring The different PIK-related kinases are involved in diverse
only at specific times and places. In the case of Hart- cellular functions, such as control of cell growth, cell
well’s unicellular yeast, growth occurs only when nutri- cycle and DNA damage checkpoints, recombination and
ents are available and only at a discrete site on the cell maintenance of telomere length. Accordingly, dysfunc-
surface (hence the name budding yeast). In neurons, tion of the PIK-related kinases results in a wide spectrum
growth in response to synaptic activity occurs specifi- of severe diseases, ranging from cancer to immunodefi-
cally at the synapse. In metazoans, the problem of ciency (Keith and Schreiber, 1995). Despite the homol-
ogy to lipid kinases, none of the PIK-related kinases has
been demonstrated to have lipid kinase activity, and* To whom correspondence should be addressed (e-mail: m.hall@
unibas.ch). both yeast and mammalian TOR, if not all the PIK-related
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Figure 1. Architecture of a Generic TOR Protein
The domain structure is based on yeast TOR1 and TOR2 and mam-
malian TOR (mTOR).
kinases, are Ser/Thr protein kinases. A target phosphor-
ylation site for yeast TOR remains to be determined.
mTOR has been shown to phosphorylate a (Ser/Thr)-
Pro motif (Brunn et al., 1997) or a threonine flanked by
bulky hydrophobic residues (Burnett et al., 1998; Isotani
Figure 2. TOR Controls a Large and Diverse Set of Growth-Relatedet al., 1999).
ReadoutsThe FKBP-rapamycin complex, which inhibits TOR
Green arrows indicate activation; red bars indicate repression.function, interacts with the FRB (FKBP-rapamycin bind-
Shown is a composite of yeast and mammalian readouts.ing) domain in TOR, adjacent to the catalytic kinase
domain (Figure 1). Both original point mutations (TOR1–1
and TOR2–1) that enable yeast cells to grow on rapa-
last few years, yeast and mammalian TOR has been
mycin-containing medium reside within the FRB do-
demonstrated to control several additional readouts, all
main. The resulting amino acid substitutions (including
of which are related to cell growth. These readouts in-
the corresponding substitution in mTOR) prevent the
clude organization of the actin cytoskeleton, membrane
binding of the FKBP-rapamycin complex to TOR, ex-
traffic and protein degradation, PKC signaling, ribosome
plaining the ability of the mutations to confer complete
biogenesis, transcription, and, although more a conse-
resistance to rapamycin (Stan et al., 1994; Chen et al.,
quence than a readout, cancer (Figure 2). The mecha-
1995; Choi et al., 1996).
nisms by which TOR regulates such diverse readouts
In addition to their catalytic and FRB domains, TOR
in response to nutrients are not known in all cases, but
proteins also contain up to 20 tandemly repeated HEAT
for some readouts, effectors or signaling mechanisms
motifs at their N terminus, roughly grouped into two
have been elucidated and will be described further
blocks (Andrade and Bork, 1995) (Figure 1). Each HEAT
below.
motif comprises approximately 40 amino acids that form
The studies that have described the various growth-
a pair of antiparallel a helices (Groves et al., 1999). HEAT
related TOR readouts have relied extensively on the
motifs have been proposed to mediate protein–protein
use of rapamycin to inhibit TOR. In this context, it is
interactions in multiprotein complexes (Andrade and
important to note that rapamycin is highly TOR specific.
Bork, 1995). More recently, a so-called FAT domain,
TOR mutations that prevent FKBP-rapamycin binding
spanning approximately 500 amino acids N-terminal to
confer complete resistance to the growth-inhibitory
the FRB and catalytic domains in TOR, has been pro-
properties of rapamycin. Furthermore, in all cases exam-
posed (Bosotti et al., 2000) (Figure 1). The function of
ined, these TOR mutations have reversed the inhibitory
the FAT domain, found only in members of the PIK-
effects of rapamycin on the TOR readouts.
related kinase family, remains to be elucidated. Ac-
cording to current speculation, the domain could serve
Translation Initiation
as a scaffold or as a protein–protein interaction domain,
mTOR, in response to amino acids and growth factors,
similar to the HEAT repeats. Indeed, the large size of
controls the mammalian translation machinery via acti-
TOR suggests that it may have several interaction part-
vation of the p70s6k protein kinase and via inhibition of
ners which contribute to its regulation or signaling. Fi-
the eIF4E inhibitor 4E-BP1 (also known as PHAS-I) (see
nally, the PIK-related kinases contain a short (z35 amino
Thomas and Hall, 1997; Hara et al., 1998) (Figure 3).
acids) extreme C-terminal sequence that has been
Activation of p70s6k and resulting phosphorylation of the
termed a FATC domain (Keith and Schreiber, 1995; Bo-
40S ribosomal protein S6 ultimately drives translation
sotti et al., 2000) (Figure 1). The FATC domain occurs
of 59 TOP (terminal oligopyrimidine tract) mRNAs (Jeffer-
only in combination with the FAT domain and may be
ies et al., 1997). These mRNAs constitute a small family
important for catalytic activity of PIK-related kinases.
of abundant transcripts (up to 20% of cellular mRNA)
that encode primarily ribosomal proteins and compo-
nents of the translational apparatus (Meyuhas et al.,TOR Readouts
The immunosuppressant and antibiotic rapamycin po- 1996). Thus, by controlling 59 TOP mRNA translation,
mTOR upregulates the translational machinery undertently inhibits growth in several evolutionarily diverse
cells, suggesting that TOR has a conserved role in con- favorable growth conditions. Early studies demonstrated
that activation of p70s6k is potently inhibited by rapa-trolling cell growth. What are the growth-related read-
outs controlled by TOR? Early findings, as reviewed mycin, suggesting that mTOR is an upstream regulator
of p70s6k (see Pullen and Thomas, 1997). However, it hasbelow, indicated that TOR is dedicated to activating
translation initiation in response to nutrients. Within the become clear that regulation of p70s6k activity is very
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Figure 3. Model of mTOR Effectors and Signaling Pathways in Mam- Figure 4. Model of TOR Effectors and Signaling Pathways in Yeast
malian Cells Arrows indicate activation; bars indicate repression. rap is rapa-
mycin; PPase refers to protein phosphatase (type 2A or type 2A-Arrows indicate activation; bars indicate repression. The dashed
arrow between PKB and mTOR reflects the uncertainty as to whether related). SAC7 is a GTPase-activating protein (GAP) for RHO1.
PKB controls mTOR (see text). rap is rapamycin; X refers to an
unidentified kinase.
TOR1 and TOR2 proteins activate translation initiation
most likely via the initiation factor eIF4E (Barbet et al.,complex, involving a hierarchical phosphorylation of
several sites in p70s6k by different kinases (Pullen and 1996; Cosentino et al., 2000) (Figure 4). The G1 cell cycle
arrest observed upon TOR inactivation is a consequenceThomas, 1997; Alessi et al., 1998; Pullen et al., 1998).
Rapamycin principally affects only one of these sites of a translation defect, emphasizing that growth-induced
synthesis of cell cycle machinery components, such as(Thr389 or Thr412, depending on the numbering system),
which is one of the early sites in the phosphorylation the yeast G1 cyclin CLN3, plays an important role in
activating and allowing progression of the cell cyclehierarchy (reviewed in Pullen and Thomas, 1997; Weng
et al., 1998). Recently, mTOR has been shown in vitro (Barbet et al., 1996). These findings also support the
notion that cell growth and cell proliferation are indeedto phosphorylate p70s6k directly, but it remains to be
determined whether this phosphorylation is physiologi- distinct, yet coupled processes.
Rapamycin treatment or TOR depletion results in sev-cally relevant in vivo (Burnett et al., 1998; Isotani et al.,
1999). 4E-BP1 is a translation inhibitor that is phosphor- eral physiological changes characteristic of starved (G0)
cells, in addition to a downregulation of translation andylated and inactivated in response to a growth signal.
Phosphorylated 4E-BP1 dissociates from eIF4E, the a G1 arrest, including an accumulation of storage carbo-
hydrates (e.g., glycogen) and an altered transcriptiontranslation initiation factor that binds the cap structure
(m7G(59)ppp(59)N) present at the 59 termini of mRNAs, pattern (Barbet et al., 1996) (Figure 2). The striking simi-
larities between starved and rapamycin-treated cells es-thereby allowing cap-dependent translation. Rapamycin
blocks both 4E-BP1 phosphorylation and cap-depen- tablished the concept that the TOR signaling pathway
controls cell growth in response to nutrients (Barbet etdent translation (Beretta et al., 1996), and mTOR has
been demonstrated to phosphorylate 4E-BP1 directly al., 1996; Thomas and Hall, 1997).
What is upstream of TOR? In yeast, the mechanisms(discussed in further detail below) (Brunn et al., 1997).
Thus, mTOR also controls eIF4E function, which is par- and molecules regulating TOR in response to nutrients
are unknown. In mammalian cells, the regulation of TOR,ticularly important in the translation of mRNAs con-
taining a highly structured 59 untranslated region (UTR), in response to amino acids and growth factors, is con-
troversial. One of the main signaling pathways activatedsuch as the transcripts encoding cyclin D1 and the
c-myc oncogene (Sonenberg and Gingras, 1998). in response to a growth factor involves the insulin recep-
tor, insulin receptor substrates (IRS), and PI3K. Down-p70s6k and 4E-BP1 phosphorylation are dependent on
the availability of amino acids, in addition to a growth stream of PI3K, the growth-controlling pathway includes
39-phosphoinositide-dependent protein kinase 1 (PDK1),factor, in the medium. A truncation mutation in p70s6k
confers resistance to rapamycin and resistance to inhi- Protein Kinase B (PKB, also known as Akt), and p70s6k
(Figure 3). PDK1 phosphorylates a threonine in thebition by amino acid withdrawal, indicating that amino
acid availability, like rapamycin, may impinge on p70s6k activation loops of PKB and p70s6k. The PDK1-medi-
ated phosphorylation of PKB activates PKB in concertand 4E-BP1 via mTOR (Hara et al., 1998) (Figure 3).
Thus, like yeast TOR (see below), mTOR signals to the with 39-phosphoinositide binding to the PKB pleckstrin
homology domain (reviewed in Vanhaesebroeck andtranslation machinery in response to nutrients.
In yeast, rapamycin treatment or inactivation of both Alessi, 2000). Studies with the PI3K inhibitor wortmannin
and with rapamycin have suggested a model in whichTOR genes results in a severe decrease in translation
initiation and an arrest in the early G1 phase of the cell PI3K and PKB signal to p70s6k and 4E-BP1 via mTOR
(see Thomas and Hall, 1997). According to this model,cycle (Kunz et al., 1993; Barbet et al., 1996). The yeast
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mTOR would be activated by PKB. Indeed, recent stud- uptake is a consequence of the vacuolar degradation
of high affinity amino acid permeases such as the yeasties have presented evidence that insulin stimulates
phosphorylation and activity of mTOR via PKB (Scott et tryptophan transporter TAT2. The turnover of plasma
membrane TAT2 requires ubiquitination, endocytosis,al., 1998), and that mTOR is a direct substrate of PKB
(Nave et al., 1999). However, other studies have failed and finally vacuolar proteases. Interestingly, upon rapa-
mycin treatment or starvation, an intracellular pool ofto detect significant alteration in mTOR autokinase ac-
tivity or mTOR-associated 4E-BP1 kinase activity in re- TAT2 is routed to the vacuole independently of the
plasma membrane, indicating that TOR controls not onlysponse to amino acids or insulin (Hara et al., 1997, 1998).
Gingras et al. (1999) have proposed a model in which stability of nutrient permeases which already reside at
the plasma membrane, but also the intracellular sortingmTOR kinase activity is largely constitutive. According
to this model, mTOR-mediated phosphorylation of 4E- of nutrient transporters to their final destination. Further-
more, TOR regulation of TAT2 stability and sorting isBP1 is a prerequisite for growth factor-induced PKB-
mediated full phosphorylation of 4E-BP1 (Gingras et al., inverse to that of GAP1. GAP1 is a general amino acid
permease that is upregulated by TOR inactivation or1999) (Figure 3). mTOR may be regulated at the level of
localization or substrate availability, in addition to or nutrient deprivation and sorted to the plasma membrane
(Beck et al., 1999). Control of the inverse regulation ofrather than at the level of intrinsic kinase activity. mTOR
interacts with gephyrin, a protein necessary for the clus- specific (e.g., TAT2) and broad-range (e.g., GAP1) per-
meases by TOR selectively coordinates amino acid im-tering of glycine receptors at the cell membrane in neu-
rons. Coexpression of mTOR and gephyrin in HeLa cells port and growth. For other nutrients, such as ammonium
or glucose, the situation may be analogous, with TORcauses mTOR, normally evenly distributed, to aggregate
in large cytoplasmic clumps (Sabatini et al., 1999). Pe- controlling stability and sorting of the corresponding
permeases according to the prevailing nutrient condi-terson et al. (2000) have suggested that rapamycin inhib-
its mTOR by altering mTOR localization or by disrupting tions.
Autophagy is the process by which cytoplasmic com-the association between mTOR and a substrate. Thus,
the mechanism(s) by which TOR is regulated remains ponents are delivered in bulk to the lysosome/vacuole
for degradation. Autophagy is induced upon nutrientto be determined.
starvation to downregulate ribosomes and other cyto-
plasmic components, but also occurs at a basal level inActin Organization
yeast during vegetative growth to eliminate old proteinsIn yeast, TOR2 (but not TOR1) additionally controls cell
and organelles. This bulk protein degradation processcycle–dependent polarization of the actin cytoskeleton.
involves the formation of autophagosomes, vesicularThis TOR2-unique function is rapamycin-insensitive and
membrane structures that deliver cytoplasmic materialmediates the polarized growth characteristic of budding
to the lysosome/vacuole. Inactivation of TOR in yeastyeast cells (Zheng et al., 1995; Schmidt et al., 1996).
or mammalian cells leads to induction of autophagy,Genetic and biochemical evidence has shown that TOR2,
even in nutrient-rich medium, indicating that TOR nega-via the exchange factor ROM2, activates the RHO1
tively controls starvation-induced autophagy (Blom-GTPase (Schmidt et al., 1997). RHO1, in turn, signals to
maart et al., 1995; Noda and Ohsumi, 1998). In yeast,the actin cytoskeleton via its direct effector PKC1 and
TOR prevents autophagy probably by inhibiting one ora PKC1-activated MAP kinase cascade (Helliwell et al.,
more of the autophagy-mediating APG gene products.1998a, 1998b) (Figure 4). A similar function of TOR ki-
The APG proteins form a novel protein-degradationnases has not been identified in any other organism and
pathway, similar to the ubiquitin-conjugation systemmay reflect the so far unique situation of two TOR genes
(Mizushima et al., 1998).in yeast. The finding that yeast TOR controls both trans-
Under favorable growth conditions, TOR promoteslation and organization of the actin cytoskeleton indi-
protein synthesis and inhibits protein degradation (nutri-cates that TOR integrates temporal and spatial control
ent transporter turnover and autophagy). Upon unfavor-of cell growth. Temporal control is via protein synthesis
able conditions, TOR is inactive, leading to a reductionwhereas spatial control is via organization of the actin
in protein synthesis and an upregulation of protein deg-cytoskeleton. Coordination of these two parameters is
radation. Thus, TOR maintains a balance between pro-essential to ensure that cell growth occurs only at the
tein synthesis and degradation such that the cell canappropriate time and location in the cell.
rapidly adjust mass accumulation to a level appropriate
to the nutrient supply (reviewed in Dennis et al., 1999).Membrane Traffic and Protein Degradation
Delivery of nutrient transporters to the cell surface and
uptake of nutrients are essential for cell growth and Protein Kinase C Signaling
Protein Kinase C (PKC) family members play centralviability. These events are adapted to environmental
conditions to optimize nutrient flow and cell growth. regulatory roles in a multitude of cellular processes,
including cell growth and proliferation, apoptosis andCoordination between the import of building blocks for
a cellular process and the process itself, e.g., amino survival, and cytoskeletal remodeling. Much attention
has focused on the regulation of mammalian PKC activ-acid import and translation, is critical to adjust the
growth rate of the cell to the nutritional conditions. ity, and especially on the phosphorylation of PKC (re-
viewed in Parekh et al., 2000). Phosphorylation of a criti-As part of the above mentioned starvation response
occurring upon TOR inactivation, rapamycin also causes cal residue in the activation loop of AGC kinase family
members, including Protein Kinase A (PKA), PKB, PKC,a severe decrease in amino acid import in yeast (Schmidt
et al., 1998; Beck et al., 1999). This drop in amino acid and p70s6k, is crucial for the activation of these kinases.
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Phosphorylation of other sites, for instance a C-terminal II, and III), rRNA processing, and translation. The finding
that TOR positively controls both the biosynthesis andhydrophobic site, also contributes to the full activation
of PKC isozymes. Recently, the phosphorylation of the activity of the translation machinery underscores the
central role of TOR in mediating cell growth.conserved C-terminal hydrophobic site in classical
PKCa and in novel PKCd has been shown to be positively
controlled by TOR. Similar to Thr389 in p70s6k, the phos-
Transcriptionphorylation of the hydrophobic site in PKC is sensitive
Upon nutrient limitation, yeast cells enter a quiescentto rapamycin. The kinase responsible for the rapamycin-
(stationary) phase characterized not only by a reductionsensitive phosphorylation of classical and novel PKC
in protein synthesis and many other distinctive pheno-isozymes was identified as atypical PKC complex, indi-
types, but also by an altered transcription pattern. Mostcating that TOR controls either this atypical PKC or an
genes transcribed by RNA PolI, II and III are downregu-antagonizing phosphatase (Ziegler et al., 1999). Impor-
lated in G0. However, a relatively few PolII-transcribedtantly, and again in agreement with previous findings
genes, important for survival under nutrient-limiting con-for p70s6k, amino acid availability impinges on the rapa-
ditions, are induced. TOR, in addition to positively con-mycin-sensitive hydrophobic site in at least novel PKC,
trolling PolII-mediated transcription of ribosomal proteinfurther implicating mTOR in the response to nutrients
genes, also negatively controls PolII-mediated tran-(Parekh et al., 1999).
scription specific to starved cells (Barbet et al., 1996;Recent evidence has involved novel PKCd in the
Beck and Hall, 1999; Cardenas et al., 1999; HardwickmTOR-4E-BP1 signaling pathway, i.e., in the control of
et al., 1999). The general mechanism by which TORcap-dependent translation initiation (Kumar et al., 2000).
negatively controls starvation-specific PolII transcrip-PKCd interacts with mTOR, is required for the phosphor-
tion is by preventing nuclear localization of nutrient-ylation (and inhibition) of 4E-BP1, and promotes cap-
responsive transcriptional activators (see below fordependent translation initiation. However, unlike mTOR,
further details) (Beck and Hall, 1999). Thus, TOR alsoPKCd does not directly phosphorylate 4E-BP1. The role
controls growth via transcriptional regulation of nutrientof PKCd in the mTOR-4E-BP1 pathway remains to be
metabolism.further elucidated.
In mammalian cells, mTOR controls the transcriptional
activator STAT3 (Figure 3). Maximal activation of STAT3,
Ribosome Biogenesis and tRNA Synthesis in response to the cytokine CNTF (ciliary neurotrophic
Ribosome synthesis, a major consumer of the cell’s re- factor), requires tyrosine and serine phosphorylation.
sources, is the classic growth-related readout. Upregu- Tyrosine phosphorylation is mediated by members of
lation of ribosome synthesis occurs in response to favor- the JAK/Tyk family of kinases. Serine phosphorylation
able conditions and allows a cell to grow faster—but of STAT3, and STAT3-dependent transcription, is rapa-
only if all components of the ribosome and other essen- mycin-sensitive. The activation of STAT3 by mTOR may
tial machineries are coordinately available. Thus, ribo- be direct, as mTOR efficiently phosphorylates the rele-
some synthesis reflects many regulatory decisions a cell vant serine (Ser727) in a STAT3 peptide (Yokogami et
must make when determining whether to grow and, if al., 2000).
so, at what rate (Warner, 1999).
In mammalian cells, the mTOR-p70s6k signaling path-
way induces synthesis of ribosomal proteins by stimulat- Cancer
Several lines of evidence have implicated mTOR in can-ing translation of 59 TOP mRNAs, as discussed above.
Earlier studies have indicated that rRNA synthesis in cer. First, although an oncogenic version of mTOR has
yet to be found, many of the proteins linked to TORmammalian cells is rapamycin-sensitive and thus also
controlled by mTOR (Mahajan, 1994; Leicht et al., 1996). signaling, such as PI3K, PKB, and eIF4E, have been
identified in oncogenic versions or demonstrated to havemTOR positively controls RNA Polymerase I (PolI, large
rRNA transcription) and RNA Polymerase III (PolIII, 5S transforming potential (see Thomas and Hall, 1997). Sec-
ond, mTOR controls translation of c-Myc, a transcriptionrRNA, and tRNA transcription) activity, possibly via inac-
tivation of the retinoblastoma protein (pRb). pRb inhibits factor often deregulated in tumors. c-Myc target genes
govern several growth-related processes including rRNAPolI and PolIII transcription (reviewed in White, 1997),
and pRb phosphorylation and inactivation are blocked transcription and processing, ribosomal protein tran-
scription, and translation (reviewed in Schmidt, 1999)—upon rapamycin treatment (Hashemolhosseini et al.,
1998) (Figure 3). processes remarkably similar to the growth-related
readouts of TOR. mTOR mediates translational induc-TOR also regulates ribosome biogenesis in yeast. Ra-
pamycin treatment rapidly and severely reduces RNA tion of c-myc, in response to serum, via phosphorylation
and inhibition of 4E-BP1 (West et al., 1998). Third,Polymerase II (PolII)-mediated transcription of genes en-
coding ribosomal proteins (Cardenas et al., 1999; Hard- STAT3, whose activation is controlled by mTOR (see
above), is persistently activated in many human cancerswick et al., 1999; Powers and Walter, 1999). Yeast TOR
also controls rRNA and tRNA synthesis, via PolI and and causes cellular transformation (Bromberg et al.,
1999). Fourth, malignant transformation by the nonre-PolIII, and processing of at least the 35S precursor rRNA
(Zaragoza et al., 1998; Powers and Walter, 1999) (Figure ceptor tyrosine kinase v-Src is mediated via the Ras-
MAPK pathway and the PI3K-mTOR pathway (Penuel4). Thus, combining the evidence obtained in mamma-
lian systems and the latest results from yeast, the TOR and Martin, 1999). Fifth, a constitutively active mTOR-
p70s6k signaling pathway has been shown to be responsi-signaling pathway plays an essential role in controlling
ribosome biogenesis at many levels: transcription (PolI, ble for the transformed state of pancreatic cancer cells
Cell
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(Grewe et al., 1999). Sixth, mitogen-stimulated downreg- maintain p70s6k, 4E-BP1 and PKC isozymes phosphory-
lated (Hara et al., 1997, 1998; Parekh et al., 1999; Pe-ulation of the cyclin-dependent kinase inhibitor p27Kip1
is prevented by rapamycin (Nourse et al., 1994; Luo et terson et al., 1999, 2000).
Yeast TOR also controls starvation-specific transcrip-al., 1996). Finally, some neuroblastoma and glioblas-
toma cells are particularly sensitive to rapamycin (Hosoi tion by sequestering the redundant zinc-finger transcrip-
tion factors MSN2 and MSN4 in the cytoplasm. MSN2/4et al., 1998). The above findings also suggest that rapa-
mycin may provide a novel therapeutic approach in can- activate a large number of genes in response to several
types of stress, including carbon limitation. TOR seques-cer treatment. The involvement of mTOR signaling in
cancer further illustrates the link between cell growth ters the carbon-responsive factors MSN2/4 in the cyto-
plasm by a mechanism similar to that by which PKBand proliferation.
and 14-3-3 proteins inactivate the growth-inhibiting or
proapoptotic Forkhead transcription factors in mamma-TOR Effectors and Signaling Mechanisms
lian cells (Brunet et al., 1999; Kops et al., 1999). In re-The TOR effectors and signaling mechanisms mediating
sponse to a good carbon source, TOR promotes thethe growth-related readouts described above are known
association of MSN2/4 with the cytoplasmic 14-3-3 pro-in some, but not all cases. mTOR signals to the transla-
tein BMH2 (Bertram et al., 1998; Beck and Hall, 1999).tion initiation machinery via p70s6k and 4E-BP1, as de-
TOR-mediated control of MSN2/4 is independent ofscribed above. In yeast, TOR signals to the translation
TAP42 and SIT4 (Beck et al., 1999) (Figure 4). TOR maymachinery via TAP42, an essential protein homologous
control MSN2/4 in conjunction with the RAS-PKA path-to the murine a4 phosphoprotein. TAP42 associates, in a
way, as nuclear localization of MSN2/4 is also controlledTOR- and nutrient-dependent manner, with the catalytic
negatively by PKA (Gorner et al., 1998). Interestingly, assubunits of type 2A or type 2A-related (SIT4) protein
TOR controls MSN2/4 and GLN3 via different effectorphosphatases (PP2As), and mutations in the TAP42
pathways and in response to different types of starva-gene confer dominant rapamycin resistance (Di Como
tion, TOR appears to discriminate between nitrogen andand Arndt, 1996). Similar a4-phosphatase complexes
carbon starvation.are present in mammalian cells, but there is substan-
The effector pathways by which yeast and mammaliantial controversy regarding the rapamycin-sensitivity of
TOR controls other readouts, such as PolI/III transcrip-these complexes (Murata et al., 1997; Chen et al., 1998;
tion and rRNA processing, are not known. The observa-Inui et al., 1998; Nanahoshi et al., 1998). TAP42 has been
tion that yeast PP2A mutants are defective in ribosomedemonstrated to be directly phosphorylated by TOR2
biogenesis suggests that TOR controls several, but notand this phosphorylation promotes formation of the
necessarily all, readouts via TAP42-PP2A (Zaragoza etTAP42-PP2A complex (Jiang and Broach, 1999) (Figure
al., 1998; Powers and Walter, 1999) (Figure 4). Future4). The mechanism by which TAP42 signals to activate
studies may reveal additional TOR effector pathways, orprotein synthesis is unknown. TAP42 also mediates the
TOR cross-talk with other growth-controlling pathways.TOR signal controlling nutrient permease stability and
sorting. In the case of the tryptophan transporter TAT2,
TAP42 regulates the phosphorylation state of the Ser/ Growth Control in Metazoans
All the studies reviewed above pertain to growth controlThr kinase NPR1. Under favorable nutrient conditions,
TOR and TAP42 maintain NPR1 in an inactive, phosphor- in single cells, yeast and cultured mammalian cells.
However, control of cell growth is also important in de-ylated state. Upon rapamycin treatment or nutrient dep-
rivation, NPR1 is dephosphorylated and activated, re- termining overall organ and body size in multicellular
systems. Animals attain characteristic body size andsulting in the degradation of TAT2 and the stabilization
of the general amino acid permease GAP1 (Schmidt et proportions via the coordinate regulation of cell growth,
cell proliferation, and cell death (Conlon and Raff, 1999).al., 1998; Beck et al., 1999) (Figure 4).
In yeast, TOR globally represses starvation-specific How is cell growth controlled within the context of
overall body size in multicellular organisms? Recent re-transcription by sequestering several nutrient-respon-
sive transcription factors in the cytoplasm. TOR pre- sults from the fruit fly Drosophila have begun to answer
this question and have, albeit so far only indirectly, impli-vents transcription of genes normally induced upon ni-
trogen limitation by promoting association of the GATA cated TOR. Manipulation of members of the PI3K signal-
ing pathway in Drosophila alters organ and organismtranscription factor GLN3 with the cytoplasmic URE2
protein. The binding of GLN3 to URE2 requires TOR- size, indicating that this pathway controls cell size
(growth) and/or number (proliferation and death) (re-dependent phosphorylation of GLN3 and/or URE2 (Beck
and Hall, 1999; Cardenas et al., 1999; Hardwick et al., viewed in Edgar, 1999 and in Weinkove and Leevers,
2000). Drosophila PI3-kinase (Dp110-Dp60) and its di-1999). Phosphorylation and cytoplasmic retention of
GLN3 are also dependent on the TOR effector TAP42, rect regulator, the IRS1–4 homolog CHICO, control cell
size and cell number (Leevers et al., 1996; Bohni et al.,and are antagonized by the phosphatase SIT4 (Beck
and Hall, 1999). The similarities in the regulation of 1999; Weinkove et al., 1999). Interestingly, manipulation
of the more distal component of the pathway p70s6kGLN3 and NPR1 suggest a general model for TOR-medi-
ated signaling. According to this model, TOR inhibits (DS6K) affects cell size, but not cell number (Montagne
et al., 1999). Importantly, DS6K mutant flies (dS6K) arephosphatases, via formation of a TAP42-PP2A complex.
Upon inactivation of TOR, the TAP42-PP2A complex reduced in body size but perfectly formed, suggesting
that p70s6k controls body size but not body proportionsdissociates, and the released phosphatase dephos-
phorylates and thereby activates GLN3 and NPR1 (Fig- (Montagne et al., 1999). Perfectly proportioned “micro-
flies” also develop under starvation conditions, sug-ure 4). In mammalian cells, mTOR has also been pro-
posed to negatively regulate PP2A as a mechanism to gesting that body size is controlled in response to
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nutrients, independently of patterning, cell-fate specifi- conserved from yeast to man. TOR may be a key signal-
ing molecule utilized by many, if not all, organisms tocation, or cell differentiation (see Edgar, 1999). The role
of PKB (DAkt1) in controlling cell size and/or number is control growth in response to nutrients.
unclear as it has been reported to affect only cell size
(Verdu et al., 1999), or both cell size and number (H. Concluding Remarks
Stocker and E. Hafen, as cited in Leevers, 1999). PI3K, The multitude and diversity of growth-related readouts
CHICO, DAkt1, and DS6K control cell size in a cell- controlled by TOR indicate that this conserved kinase
autonomous manner, meaning that these signaling mol- may not be simply part of a single, linear, growth-con-
ecules regulate growth of the individual cells in which trolling pathway. Indeed, as suggested by the findings
they reside rather than of other cells via production of described above, TOR may act radially on several differ-
a systemic growth factor. ent pathways. TOR may even be viewed primarily as a
How can one explain the finding that PI3K and CHICO “cross-talker” that broadly integrates cell physiology to
mutants are reduced in both cell size and cell number, elicit balanced growth. Thus, TOR can be regarded as
whereas DS6K mutants are reduced only in cell size? a central controller of cell growth.
An explanation could be that the PI3K signaling pathway
bifurcates upstream of DS6K, possibly at the level of
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